ORGANIZATION OF DRUG REIMBURSEMENT IN DIFFERENT REGIONS OF THE WORLD


Cite item

Full Text

Abstract

Drug reimbursement is one of the key elements of the effective health care system. The introduction of mechanisms to optimize the cost of drug provision can significantly reduce the costs of the state budget, expanding the availability of therapy and reducing long-term economic losses due to disability of the working population. The article analyses the specifics of drug provision programs in various regions of the world to determine the best practices for the purpose of subsequent introduction in the Russian Federation.

About the authors

S. N Puzin

Russian Medical Academy of Continuous Professional Education; I.M. Sechenov First Moscow State Medical University

125993, Moscow, Russian Federation; Moscow, 119435, Russian Federation

A. V Grechko

Federal Research and Clinical Center of Intensive Care Medicine and Rehabilitology

141534, Moscow, Russian Federation

I. V Prianikov

Federal Research and Clinical Center of Intensive Care Medicine and Rehabilitology

141534, Moscow, Russian Federation

Vladislav S. Malichenko

Federal Research and Clinical Center of Intensive Care Medicine and Rehabilitology

Email: vlad.malichenko@gmail.com
MD, PhD, Researcher FSBI “Federal Scientific and Clinical Center for Reanimation and Rehabilitation», 141534, Moscow, Russian Federation 141534, Moscow, Russian Federation

T. A Chludeeva

Department of medical and health work and insurance of the Administrative Department of the Central Bank of the Russian Federation( Bank of Russia)

107016, Moscow, Russian Federation

S. S Puzin

I.M. Sechenov First Moscow State Medical University

Moscow, 119435, Russian Federation

References

  1. Власов В.В., Плавинский С.Л. Варианты лекарственного обеспечения для России: уроки стран Европы и всего мира. Москва, 2012.
  2. CMS What’s an ACO? Centers for Medicare and Medicaid Services, 2012. (https://www.cms.gov/ACO/, accessed 19 April 2013).
  3. Pharmaceutical Research and Manufacturers of America (PhRMA). Medicare Part D: A Success Story, http://www.phrma.org/issues/medicare (accessed May 16), 2013.
  4. German Pharmaceutical Industry Association/BPI, based on 1. IMS World Review 2012.
  5. Sieler S., Rudolph T., Brinkmann-Sass C., Sear R. How has German health reform impacted pharma pricing and market access, and what can the industry learn from the experience? Country Focus. Germany. McKinsey. 2015.
  6. Workplace and Employee Survey Compendium. Statistics Canada. 2008. http://www.statcan.gc.ca/pub/71-585-x/71-585-x2008001-eng.pdf. Low Earnings, Unfilled
  7. Prescriptions: Employer-Provided Health Benefit Coverage in Canada. Wellesley Institute. 2015.
  8. Prescription drug access and affordability an issue for nearly a quarter of all Canadian households. Angus Reid Institute. 2015 http://angusreid.org/
  9. The effect of cost on adherence to prescription medications in Canada. Canadian Medical Association Journal. 2012. http://www.cmaj.ca/
  10. Clinical Service Proposal: Medication Adherence Services. British Columbia Pharmacy Association. 2013. http://www.bcpharmacy.ca/uploads/Medication_Adherence.pdf
  11. Kennedy J., Morgan S. Cost-related prescription nonadherence in the United States and Canada: A system-level comparison using the 2007 international health policy survey in seven countries. Clinical Therapeutics. 2093; 1 (1): 213-9.
  12. Demers V., Melo M., Jackevicius C., Cox J., Kalavrouziotis D., Rinfret S., Humphries K., Johansen H., Tu J., Pilote L. Comparison of provincial prescription drug plans and the impact on patients’ annual drug expenditures. CMAJ. 2008; 178: 405-9.
  13. Pharmacare costing in Canada Preliminary Report: Assessment of a National Pharmacare Model Cost Estimate Study PDCI Market Access Inc. Commissioned by the Canadian Pharmacists Association January 19, 2016.
  14. Reforming private drug coverage in Canada: Inefficient drug benefit design and the barriers to change in unionized settings. Health Policy.2015. http://www.ncbi.nlm.nih.gov/pubmed/25498311
  15. Government of Ontario, Ministry of Health and Long-Term Care. Transparent Drug System for Patients Act, 2006. Legislation. MOHLTC. http://www.health.gov.on.ca/en/common/legislation/bill102/.McArthur D. The current paradigm of drug funding: a public funder’s perspective. In: Provincial Industry Payer Agreements in an Era of National Purchasing Strategies Roundtable Discussion, St. John’s, Canada, May 2013.
  16. Sapsford R. Delivering world class value for money in provincial drug system. 2009.
  17. McArthur D. The current paradigm of drug funding: a public funder’s perspective. In: Provincial Industry Payer Agreements in an Era of National Purchasing Strategies Roundtable Discussion, St.John’s, Canada, May 2013.
  18. Boehringer Ingelheim (Canada) Ltd. v. Canadian Agency for Drugs and Technologies In Health, 2008 55998 (ON SCDC). 510/08. Ontario Superior Court of Justice, Oct 29, 2008.
  19. Australian Government, Department of Health and Ageing (2013a) Annual report 2012-2013. http://www.health.gov.au/internet/main/publishing.nsf/Content/annual-report 2012-13.
  20. Australian Government, Department of Health (2019) Fees, patient contributions and safety net thresholds. History of PBS copayments and safety net thresholds. http://www.pbs.gov.au/info/healthpro/explanatory-notes/front/fee.
  21. The Commonwealth of Australia (2011) Framework for the introduction of parallel TGA and PBAC processes. http://www.pbs.gov.au/info/publication/factsheets/shared/framework-forintroduction-of-parallel-TGA-and-PBAC-processes.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2018 Eco-Vector



Согласие на обработку персональных данных

 

Используя сайт https://journals.rcsi.science, я (далее – «Пользователь» или «Субъект персональных данных») даю согласие на обработку персональных данных на этом сайте (текст Согласия) и на обработку персональных данных с помощью сервиса «Яндекс.Метрика» (текст Согласия).